Please login to the form below

Not currently logged in

Act-Accelerator outlines plans for longterm COVID-19 control

Its plan highlights key priorities as countries transition to manage the public health issue


The Access to COVID-19 Tools Accelerator (ACT-A) has announced the launch of a six-month plan, outlining how world leaders and global health agencies should work in tandem with the public and other partners, in order to aid the transition for long-term COVID-19 management.

Set up in 2020, ACT-A was launched by the World Health Organization (WHO), the President of France, the President of the European Commission and the Bill & Melinda Gates Foundation, in response to the G20’s call for a global tool to accelerate the development of tests, treatments and vaccines and to ensure equitable distribution.

ACT-A is the only end-to-end multilateral solution to the acute phase of the COVID-19 pandemic. In acknowledgement of the ever-changing nature of COVID-19, the ACT-A partnership has made efforts to adapt its ways of working, as countries move from controlling COVID-19 as a critical public health threat to the integration of long-term disease management campaigns.

Since the current ACT-Accelerator Strategic Plan & Budget: October 2021 to September 2022 runs until the end of September 2022, the partnership has set up a six-month transition plan, as outlined in its ACT-Accelerator Transition Plan (1 Oct 2022 to 31 Mar 2023).

The plan was produced as part of a consultative process with ACT-A agencies, donors, industry partners, civil society organisations and Facilitation Council members, and underscores key focus areas for the partnership’s pillars, coordination mechanisms and other core functions.

Moreover, it highlights the work to be maintained, transitioned, or kept on standby, while also supporting the work of ACT-A agencies as they adjust the financing and implementation of their COVID-19 efforts.

Centring on three areas, the next step of ACT-A partners’ work involves focusing R&D and market to ensure a pipeline for new and enhanced COVID-19 tools, as well as securing institutional arrangements for sustained access for all countries to COVID-19 vaccines, tests and treatments.

Lastly, the partners will concentrate in-country work on new product introduction and the full vaccination of priority populations, such as health care workers and the elderly, in line with national and international targets.

The plan lays out the move into mainstream partnership-level financing and resource mobilisation into the regular work of each agency for the future. Considering the aforementioned three focus areas, the ACT-A agencies have estimated a $400m requirement for their transition work spanning the next six months.

Commenting on the transition plan, WHO director-general, Dr Tedros Adhanom Ghebreyesus, said: “As the world moves towards managing COVID-19 over the long-term, ACT-A will continue to support countries by providing access to vaccines, tests, and treatments.

"But as this plan lays out, we still have a lot of work to do to achieve equitable access to these life-saving tools, with health workers and at-risk populations as our top priority.”

Article by
Fleur Jeffries

31st October 2022

From: Healthcare



Subscribe to our email news alerts


Add my company
Research Partnership

Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...

Latest intelligence

It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...